subject: Pfizer To Accelerate Integration Into The Industry "big Mac" - Pfizer - Pharmaceutical [print this page] January 26, 2009, the world's largest Drugs Manufacturer Pfizer Pharmacy Announced the acquisition through cash and stock Wyeth, total trade reached 68 billion U.S. dollars. The deal was announced last Friday to complete. Since then, Wyeth became a wholly owned subsidiary of Pfizer, and Pfizer became the world's first bio-pharmaceutical company. In China, Pfizer market share even more than other competitors to become the largest foreign pharmaceutical companies.
HC pharmaceutical industry network with map
Lot of money to consolidate the acquisition of "one man" status
As China, Australia, the United States and Canada, several governments have approved the acquisition by Pfizer, Wyeth case, the global Medicine The most shocking trade of 680 billion deal, announced settled. Pfizer has always been a large-scale acquisition is like to use the tools. The last decade, Pfizer three shots. 2000 to 85 billion U.S. dollars acquisition of Warner - Lambert and 2002 to 60 billion U.S. dollars after the acquisition of Pharmacia pharmaceutical companies, the re-acquisition of Wyeth, Pfizer also was able to sit tight in the global pharmaceutical industry, "a Brother "throne.
Investment adviser in the pharmaceutical industry where researchers Guo Li pointed out that if revenues to operators, Pfizer is already the world's largest pharmaceutical company, in 2008 it Sell Total 48400000000 U.S. dollars, while total sales of Wyeth ranked 13th in the world, is the world's ninth largest pharmaceutical companies. After the merger, their sales will exceed 70 billion U.S. dollars. Pfizer received Wyeth biopharmaceuticals and vaccines will make significant growth in sales of Ray-hui, and Wyeth also expanded by Pfizer global pharmaceutical market.
Business has been integrated into two groups
Learned that since January this year, has announced the acquisition, Pfizer and Wyeth has already begun work on the integration team. Pfizer last week after the completion of the acquisition was immediately announced a new 12-person leadership team, led by Pfizer, and Wyeth of the common component.
In business, after swallowing Wyeth, Pfizer became the industry giant, the product, including for human, animal and consumer health care, vaccines, biologics, small molecules and nutritional. Pfizer side that these operations have been integrated into two groups, bio-pharmaceuticals and diversified sectors. Among them, the scope of bio-pharmaceutical sector, including emerging markets, mature products, oncology services, generic drugs business and professional care, including vaccines. Diversified sector covers animal health, capsule products, consumer health and nutrition products.
Pfizer expects completion of the merger, expected 2011 synergies and cost savings from the 20 billion U.S. dollars, cost savings in 2012 will be further expanded to 4 billion U.S. dollars. Savings come from cost of sales, administrative and information management costs, research and development costs and manufacturing costs.
Divest part of the vaccine business in China
Pfizer and Wyeth's operations in China will be how to integrate, Pfizer side said, "will step by step." However, the first to be affected will be the animal health business one.
As Pfizer and Wyeth market in China has a lot of overlapping products, in addition to human drugs, the animal health product is one piece, specifically including swine mycoplasma pneumonia vaccine, pseudorabies vaccine, and dogs with a combined vaccine. According to available data the Ministry of Commerce, Pfizer and Wyeth combined Mycoplasma pneumonia in swine vaccine market share of 49.4% (38% of which Pfizer, Wyeth 11.4%), far higher than other competitors, ranked second Intervet bit market share was only 18.35%, other competitors were less than 10% market share. The merger will have the ability to use its scale to expand the market, then control the price.
Therefore requested the Ministry of Commerce, Pfizer, Wyeth at the same time approved the acquisition must be stripped in China (not including Hong Kong, Macau and Taiwan), Pfizer's brand suitable for the Swedish times (Respisure) and the Swiss appropriate times - Wang (RespisureOne) of swine mycoplasma pneumonia vaccine business, and within six months after approval by the trustee for the purchaser of the divested business to find and sign with sale and purchase agreement.
In addition, Pfizer China's media manager, said Zhang Jun, the two companies currently based upon the normal operation of the original program. Wyeth China also stressed the integration of the latest news out before, no change in the Chinese market.
